Biotech M&A surges as pharma races to replenish pipelines
CNBC’s article “Buying stuff like it’s going out of fashion: Biotech M&A on track for best year since pre-Covid” examines the resurgence of biopharma dealmaking, with global biotech M&A reaching $106 billion across 201 transactions so far in 2026 and on pace for its strongest year since before the pandemic. The article explores how looming patent expirations, improving public market conditions and the need for pharmaceutical companies to replenish pipelines are driving a wave of strategic acquisitions, particularly in the $1–5 billion range, as companies seek innovative assets across oncology, metabolic disease, neuroscience and other high-growth therapeutic areas.
Forbion General Partner Nanna Lüneborg, PhD, MBA, is featured as a leading industry voice, highlighting the growing preference for targeted “bolt-on” acquisitions that enable pharmaceutical companies to integrate promising products and technologies more effectively than large-scale mergers. She notes that while demand for innovation remains strong, companies are balancing near-term commercial opportunities with investments in earlier-stage assets and emerging technologies. Lüneborg also discusses Forbion’s experience with cross-border innovation models, particularly partnerships involving Chinese biotech companies, where strong scientific advances can be paired with global development expertise and infrastructure to bring promising therapies to patients worldwide.